ASCO26: Toni Choueiri, MD, KEYNOTE-654 - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

Share

Original Source(s)

ASCO26: Toni Choueiri, MD, KEYNOTE-654

  • July 1, 2026

Related Content

Rethinking the evidence for intensive surveillance after renal tumor ablation

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

  • 1 min
Factors Influencing the Severity of Pneumonitis Associated with Immune Checkpoint Inhibitors: Insights from Clinical, Radiological, and Laboratory Data in Real-World Settings